Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Gastrointestinal Dysfunctions in Parkinson's Disease: Symptoms and Treatments.

Poirier AA, Aubé B, Côté M, Morin N, Di Paolo T, Soulet D.

Parkinsons Dis. 2016;2016:6762528. doi: 10.1155/2016/6762528. Epub 2016 Dec 6. Review.

2.

Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes.

Siemens W, Becker G.

Ther Clin Risk Manag. 2016 Mar 11;12:401-12. doi: 10.2147/TCRM.S80749. eCollection 2016.

3.

Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation.

Argoff CE, Brennan MJ, Camilleri M, Davies A, Fudin J, Galluzzi KE, Gudin J, Lembo A, Stanos SP, Webster LR.

Pain Med. 2015 Dec;16(12):2324-37. doi: 10.1111/pme.12937. Epub 2015 Nov 19. Review.

4.

Evolving paradigms in the treatment of opioid-induced bowel dysfunction.

Poulsen JL, Brock C, Olesen AE, Nilsson M, Drewes AM.

Therap Adv Gastroenterol. 2015 Nov;8(6):360-72. doi: 10.1177/1756283X15589526. Review.

5.

Constipation: opioid antagonists in people prescribed opioids.

Ahmedzai SH, Boland JW.

BMJ Clin Evid. 2015 Sep 11;2015. pii: 2407.

6.

Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction.

Leppert W.

Drug Des Devel Ther. 2015 Apr 16;9:2215-31. doi: 10.2147/DDDT.S32684. eCollection 2015. Review.

7.

Morphine for the treatment of pain in sickle cell disease.

Gupta M, Msambichaka L, Ballas SK, Gupta K.

ScientificWorldJournal. 2015;2015:540154. doi: 10.1155/2015/540154. Epub 2015 Jan 12. Review.

8.

Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction.

Poulsen JL, Brock C, Olesen AE, Nilsson M, Drewes AM.

Clin Exp Gastroenterol. 2014 Sep 19;7:345-58. doi: 10.2147/CEG.S52097. eCollection 2014. Review.

9.

Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone.

Neefjes EC, van der Vorst MJ, Boddaert MS, Zuurmond WW, van der Vliet HJ, Beeker A, van den Berg HP, van Groeningen CJ, Vrijaldenhoven S, Verheul HM.

BMC Palliat Care. 2014 Aug 20;13:42. doi: 10.1186/1472-684X-13-42. eCollection 2014.

10.

Methylnaltrexone: its pharmacological effects alone and effects on morphine in healthy volunteers.

Zacny JP, Wroblewski K, Coalson DW.

Psychopharmacology (Berl). 2015 Jan;232(1):63-73. doi: 10.1007/s00213-014-3637-8. Epub 2014 May 29.

11.

The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities.

Leppert W.

Contemp Oncol (Pozn). 2012;16(2):125-31. doi: 10.5114/wo.2012.28792. Epub 2012 May 29.

12.

Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives.

Sobczak M, Sałaga M, Storr MA, Fichna J.

J Gastroenterol. 2014 Jan;49(1):24-45. doi: 10.1007/s00535-013-0753-x. Epub 2013 Feb 9. Review.

13.

Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide.

Bader S, Jaroslawski K, Blum HE, Becker G.

Clin Med Insights Oncol. 2011;5:201-11. doi: 10.4137/CMO.S4867. Epub 2011 Jul 14.

14.

Constipation in people prescribed opioids.

Ahmedzai SH, Boland J.

BMJ Clin Evid. 2010 Apr 6;2010. pii: 2407. Review.

15.

Methylnaltrexone in the treatment of opioid-induced constipation.

Greenwood-Van Meerveld B, Standifer KM.

Clin Exp Gastroenterol. 2008;1:49-58. Epub 2008 Dec 14.

16.

Update on the management of constipation in the elderly: new treatment options.

Rao SS, Go JT.

Clin Interv Aging. 2010 Aug 9;5:163-71. Review.

17.

Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation.

Deibert P, Xander C, Blum HE, Becker G.

Core Evid. 2010 Jun 15;4:247-58.

18.

Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors.

Singleton PA, Mambetsariev N, Lennon FE, Mathew B, Siegler JH, Moreno-Vinasco L, Salgia R, Moss J, Garcia JG.

J Angiogenes Res. 2010 Feb 19;2(1):5. doi: 10.1186/2040-2384-2-5.

19.

The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations.

Atkinson TM, Mendoza TR, Sit L, Passik S, Scher HI, Cleeland C, Basch E.

Pain Med. 2010 Mar;11(3):337-46. doi: 10.1111/j.1526-4637.2009.00774.x. Epub 2010 Jan 15.

20.

Opioid receptors in the gastrointestinal tract.

Holzer P.

Regul Pept. 2009 Jun 5;155(1-3):11-7. doi: 10.1016/j.regpep.2009.03.012. Epub 2009 Apr 2. Review.

Supplemental Content

Support Center